How have CSLLY shares performed in 2024?

CSL's stock was trading at $97.17 at the start of the year. Since then, CSLLY stock has decreased by 10.6% and is now trading at $86.9180. View the best growth stocks for 2024 here .

Are investors shorting CSL?

CSL saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 8,600 shares, an increase of 65.4% from the March 15th total of 5,200 shares. Based on an average trading volume of 55,100 shares, the days-to-cover ratio is currently 0.2 days. View CSL's Short Interest .

Is CSL a good dividend stock?

CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.09 per share and currently has a dividend yield of 1.24%. Read our dividend analysis for CSLLY .

How do I buy shares of CSL?

Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:CSLLY

CSL (CSLLY) Stock Price, News & Analysis

→ The #1 Opportunity of the decade? (From Behind the Markets) (Ad)

Free CSLLY Stock Alerts

$86.92

-1.04 (-1.18%)

(As of 04/18/2024 ET)

Compare

Today's Range: $86.80
▼
$88.21
50-Day Range: $86.92
▼
$99.41
52-Week Range: $71.51
▼
$105.11

Volume: 59,588 shs
Average Volume: 30,065 shs
Market Capitalization: $84.01 billion

P/E Ratio: N/A
Dividend Yield: 1.25%
Price Target: N/A

Stock Analysis Chart Financials Headlines SEC Filings Short Interest

Get CSL alerts:

CSL MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.00% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 13.97%
From $3.15 to $3.59 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.48 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for CSL.

3.0

Short Interest

Percentage of Shares Shorted
0.00% of the outstanding shares of CSL have been sold short.
Short Interest Ratio / Days to Cover
CSL has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in CSL has recently increased by 65.38%, indicating that investor sentiment is decreasing significantly.

1.7

Dividend Strength

Dividend Yield
CSL pays a meaningful dividend of 1.24%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
CSL does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, CSL will have a dividend payout ratio of 30.36% next year. This indicates that CSL will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CSLLY.

1.4

News and Social Media Coverage

News Sentiment
CSL has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for CSL this week, compared to 2 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CSL insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.03% of the stock of CSL is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for CSL are expected to grow by 13.97% in the coming year, from $3.15 to $3.59 per share.
Price to Book Value per Share Ratio
CSL has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Will this $2 AI stock double overnight?

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

Click here to learn more >>>

About CSL Stock (OTCMKTS:CSLLY)

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSLLY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CSLLY Stock News Headlines

April 3, 2024 | marketbeat.com

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment (CSLLY)

Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia

April 17, 2024 | americanbankingnews.com

Artelo Biosciences (NASDAQ:ARTL) versus CSL (OTCMKTS:CSLLY) Financial Review

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

April 16, 2024 | msn.com

How much do you need to invest in CSL shares for $8,000 in annual dividends?

April 12, 2024 | markets.businessinsider.com

UBS Sticks to Their Buy Rating for CSL (CMXHF)

April 12, 2024 | americanbankingnews.com

CSL Limited (OTCMKTS:CSLLY) Short Interest Update

April 9, 2024 | afr.com

Macquarie brokers say CSL is heading to $500 per share

April 5, 2024 | investorplace.com

CSLR Stock Earnings: Complete Solaria Beats EPS, Misses Revenue for Q4 2023

April 19, 2024 | Behind the Markets (Ad)

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

April 2, 2024 | fool.com.au

Own CSL shares? You're receiving a healthy dividend boost today!

March 28, 2024 | finance.yahoo.com

Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients

March 26, 2024 | afr.com

Blood giant CSL works up $US1 billion-plus bond deal; banks mandated

March 11, 2024 | finance.yahoo.com

CSL Ltd's Dividend Analysis

March 6, 2024 | prnewswire.com

CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season

February 15, 2024 | markets.businessinsider.com

Wilsons downgrades CSL (CMXHF) to a Hold

February 13, 2024 | fool.com.au

CSL shares tumble despite first-half earnings beat

February 13, 2024 | afr.com

What we learnt from CSL, Challenger, Seek and Breville’s results

February 13, 2024 | finanznachrichten.de

CSL Limited: Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

February 12, 2024 | fool.com.au

CSL share price on watch amid 20% profit jump

February 12, 2024 | marketwatch.com

CSL Says 1H Profit Rises, Boosts Dividend -- Update

February 12, 2024 | afr.com

CSL shrugs off trial setback to post double-digit earnings growth

February 12, 2024 | wsj.com

CSL Profit Rises, Boosts Dividend

February 12, 2024 | msn.com

CSL Limited falls after Phase 3 setback for key trial

February 12, 2024 | msn.com

Asian stocks move little in holiday-thinned trade; CSL drags on Australia

February 6, 2024 | msn.com

CSL and Arcturus’ Covid-19 booster found to prolong immunity

February 5, 2024 | finance.yahoo.com

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

January 29, 2024 | fool.com.au

Are CSL shares set for an earnings boost?

See More Headlines

Receive CSLLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:CSLLY
CUSIP: N/A
CIK: 1274152
Web: www.csl.com.au
Phone: (139) 389-1911
Fax: 61-3-9389-1434
Employees: 32,000
Year Founded: 1904

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $13.31 billion
Price / Sales: 6.31
Cash Flow: $3.10 per share
Price / Cash Flow: 28.05
Book Value: $18.48 per share
Price / Book: 4.70

Miscellaneous

Outstanding Shares: 966,510,000
Free Float: N/A
Market Cap: $84.01 billion
Optionable: Not Optionable
Beta: 0.73

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Paul F. McKenzie Ph.D. (Age 58)
MD, CEO & Executive Director
Comp: $2.75M
Ms. Joy Carolyn Linton B.Com. (Age 59)
BComm, GAICD, Grad Dip AFI, Chief Financial Officer
Comp: $2.05M
Mr. Mark Dehring
Head of Investor Relations
Mr. Gregory Boss B.S. (Age 63)
BS(Hons), J.D., Executive VP of Legal & General Counsel
Comp: $1.1M
Christina Hickie
Senior Manager of Communications
Ms. Roanne Parry
Chief Human Resources Officer
Dr. Karen Etchberger (Age 66)
Executive Vice President of Quality & Business Services
Comp: $1.03M
Ms. Jemimah Brennan
Head of Communications - Asia Pacific
Dr. Andrew D. Nash BSc (Hons) (Age 62)
GAICD, Ph.D., Senior Vice President of Research
Dr. William Mezzanotte M.D. (Age 65)
M.P.H., Executive VP & Head of Research and Development
Comp: $1.46M

Key Competitors

View All Competitors

Should I Buy CSL Stock? CSLLY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in CSL Limited:

CSL Limited operates in the pharmaceutical preparations industry, which is known for its stability and potential for growth.
CSL Limited has a diverse product portfolio, including plasma products, gene therapies, and vaccines, which can provide revenue streams from various sources.
Recent developments have shown CSL Limited's commitment to research and development, ensuring a pipeline of innovative products for the future.
CSL Limited's stock price has shown resilience and potential for growth, with a recent price of $97.17 on record date 12/31/2023.
CSL Limited has a global presence, operating in multiple countries, which can help mitigate risks associated with regional economic fluctuations.

Cons

Investors should be bearish about investing in CSL Limited for these reasons:

CSL Limited's outstanding shares information is not available, which may indicate limited transparency into the company's ownership structure.
CSL Limited's institutional ownership percentage is currently at 0, which may raise concerns about institutional confidence in the company.
CSL Limited's short percentage of float is 0, which may indicate limited interest from short-term investors in the company's stock.
CSL Limited's month-to-month change percentage in shares shorted was -0.2638, which may suggest a bearish sentiment among some investors.
CSL Limited's float size is 0, which may raise questions about the liquidity of the company's shares in the market.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these CSL pros and cons to contact@marketbeat.com.

CSLLY Stock Analysis - Frequently Asked Questions

How have CSLLY shares performed in 2024?: CSL's stock was trading at $97.17 at the start of the year. Since then, CSLLY stock has decreased by 10.6% and is now trading at $86.9180.
View the best growth stocks for 2024 here.
Are investors shorting CSL?: CSL saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 8,600 shares, an increase of 65.4% from the March 15th total of 5,200 shares. Based on an average trading volume of 55,100 shares, the days-to-cover ratio is currently 0.2 days.
View CSL's Short Interest.
Is CSL a good dividend stock?: CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.09 per share and currently has a dividend yield of 1.24%.
Read our dividend analysis for CSLLY.
How do I buy shares of CSL?: Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CSLLY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial